



Therapy	Target/Modality	Indications	Preclinical	Phase 1	Phase 1 Expand/ Phase 2	Phase 2 Reg/ Phase 3	Regulatory Designations
Magrolimab + Azacitidine	CD47 antibody	MDS				 FortySeven ¹	  
Pelabresib + Ruxolitinib	BET small molecule	MPN				 Constellation ² PHARMACEUTICALS	 
Ziftomenib	Menin small molecule	NPM1 mutant AML				 KURA ³ ONCOLOGY	
AFM13 + NK-cells	CD30/CD16A bispecific engager	CD30+ lymphoma			 AFFIMED		
IO-202 + Azacitidine	LILRB4 antibody	AML/CMML		 IMMUNE-ONC therapeutics			 
STRO-001	CD74 antibody drug conjugate	NHL/MM		 SUTRO BIOPHARMA			
ICT01	BTN3A antibody	heme malignancies		 ImCheck therapeutics			
RVU120	CDK8/19 small molecule	AML/MDS		 RYVU THERAPEUTICS			
BI-1206 + Rituximab	FcγRIIB antibody	NHL		 BioInvent			
BI-1808 +/- Pembrolizumab	TNFR2 antibody	CTCL		 BioInvent			
PVX-410 + ACY-241 +/- Len	XBP1/CD138/CS1 vaccine	Smoldering myeloma		 OncoPep			
BTX-1188	GSPT1 + IKZF1/3 degrader	AML/NHL		 biotheryx			
KT-333	STAT3 degrader	PTCL/CTCL/LGLL		 KYMERA			
KT-413	IRAKIMiD degrader	MYD88 mutant DLBCL		 KYMERA			
Bexmarilimab + Azacitidine	Cleaver-1 antibody	AML/MDS		 FARON			
DR-01	CD94 antibody	LGLL & cytotoxic lymphomas		 dren bio			
IMT-009	CD161 antibody	NHL		 Immunitas THERAPEUTICS			
CB-010	CD19/PD1 KO allogeneic CAR	NHL		 CARIBOU BIOSCIENCES®			  
CB-011	BCMA armored allogeneic CAR	MM		 CARIBOU BIOSCIENCES®			
CB-012	CLL-1 armored allogeneic CAR	AML	 CARIBOU BIOSCIENCES®				
TBD	<i>in vivo</i> CAR-X	TBD	 ABINTUS				
TBD	CAR macrophage	TBD	 carisma THERAPEUTICS				

1: Acquired by Gilead ♦ 2: Acquired by Morphosys ♦ 3: Licensed from University of Michigan

 Orphan Drug ♦  Fast Track ♦  Breakthrough Therapy or Regenerative Medicine Advanced Therapy (RMAT)